US regulators filed a lawsuit Tuesday to block biopharmaceutical firm Amgen's proposed $28 billion takeover of drug maker Horizon Therapeutics, saying the transaction would harm consumers.
May 16, 2023
0
33
US biopharmaceutical firm Amgen said Monday it has reached agreement to acquire Horizon Therapeutics, which specializes in medicine for rare and auto-immune diseases, for $27.8 billion.
Dec 12, 2022
0
1
(HealthDay)—For children with metastatic MYCN-nonamplified neuroblastoma (NBL-NA) diagnosed at age 18 months or older, increased expression of tumor-associated inflammatory genes seems to correlate with poor prognosis, ...
Aug 29, 2012
0
0
Federal regulators on Friday approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases.
Sep 23, 2016
0
3
The University of Texas MD Anderson Cancer Center and Amgen have announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a "bridge" ...
Jan 13, 2015
0
5
Amgen Inc. said Tuesday that its second-quarter profit dipped 1 percent as higher spending on research, production and other items offset rising sales of its medicines.
Jul 30, 2013
0
0
Federal health advisers said Wednesday that a highly-anticipated cholesterol-lowering drug from Amgen Inc. should be approved for patients with dangerously high levels of the artery-clogging substance.
Jun 10, 2015
0
3
A federal appeals court has ruled that Novartis can begin selling its lower-cost copy of an Amgen Inc. drug in September, rejecting a bid to further delay the launch of the knock-off biotech medication.
Jul 21, 2015
0
4
Canadian drugmaker Valeant will work with British competitor AstraZeneca on a potential treatment for psoriasis a few months after biotech giant Amgen said it was ending research on the drug because of a link to suicidal ...
Sep 1, 2015
0
3
(HealthDay)—For patients with early breast cancer, a response-guided neoadjuvant chemotherapy approach seems beneficial, according to a study published online Sept. 3 in the Journal of Clinical Oncology.
Sep 7, 2013
0
0
